Menu
  • Join
  • Login
  • Contact
 

Search abstracts


EVALUATION OF THE EFFICACY AND SAFETY FOR CHRONIC HEPATITIS C TREATED WITH ELBASVIR/GRAZOPREVIR

  • At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
  • Type: Poster
  • By: TSAI, Tzu-Cheng (Chang Gung Memorial Hospital, Pharmacy, China Taiwan)
  • Co-author(s): Tzu-Cheng Tsai: Pharmacy, Chang Gung Memorial Hospital, China Taiwan
    Hui-Yu Chen: Pharmacy, Chang Gung Memorial Hospital, China Taiwan
    Shin-Tarng Deng: Pharmacy, Chang Gung Memorial Hospital, China Taiwan
    Chao-Wei Hsu: Gastroenterology and Hepatology, Chang Gung Memorial Hospital, China Taiwan
  • Abstract:

    Background

    Elbasvir/grazoprevir (EBR/GZR) is a new generation, fixed-dose, combination antiviral drug used in chronic hepatitis C virus (HCV) genotype (GT) 1 or 4 infection.

    Methods

    This is a retrospective observational study. Patients were recruited who had received EBR/GZR for chronic HCV GT 1 between June 2017 and April 2018. Patients’ age, sex,

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 13 May 2019

FIP Congresses